Floatz logo

Cetuximab

Neurofibromatosis Type 2

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Neurofibromatosis Type 2 cohort.

Asset / SponsorPhaseRating
Temsirolimus
M.D. Anderson Cancer Center
Phase 1CC
Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]-
Ikena Oncology
Phase 1CC
Valproic Acid
M.D. Anderson Cancer Center
Phase 1CC
Osimertinib
Ikena Oncology
Phase 1CC
st002
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
N/ANR

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →